Hollis-Eden Pharmaceuticals, Inc.

	Nasdaq (SC): HEPH	Change symbol:

PROFILE Hollis-Eden Pharmaceuticals is a development-stage pharmaceutical company focusing on drugs for the treatment of infectious diseases and immune system disorders such as HIV and AIDS, hepatitis B and C, and malaria. The company's lead product, HE2000 (which is in clinical trials), strives to inhibit HIV replication, strengthen the immune system, and reduce the viral load of infected patients. Hollis-Eden has a collaborative agreement with and owns some 21% of Aeson Therapeutics, which is developing drugs with properties similar to HE200's. The company uses outside contractors to manufacture its products. Founder and CEO Richard Hollis owns almost 30% of the company.  COMPETITION Biokeys Pharmaceuticals Inc. (BKYS) Centocor, Inc. (dossier) Triangle Pharmaceuticals, Inc. (VIRS)		STOCK ANALYSIS  View by:  Day   Day   Month   Month   Year   Year  FURTHER ANALYSIS • Advanced Charting • Deals  FINANCIAL OVERVIEW Fiscal Year-End: December 2000 Sales (mil.): 0.10 1-Yr. Sales Growth: 0.0% Employees: 35 Revenue per employee: $2,857.14  KEY PEOPLE • Richard B. Hollis     CEO • Daniel D. Burgess     CFO  CONTACT INFO 9333 Genesee Ave., Ste. 200 San Diego, CA 92121 US Phone: 858-587-9333 Fax: 858-558-6470 Online: Web Site

	Company Data   News, quotes & more

		Hoover's Company Capsule Copyright © 2001, Hoover's Inc. Austin, Texas. For changes and updates, contact Hoover's directly.